Delcath Systems Q2 2023 Earnings Report

Delcath Systems EPS Results

• Actual EPS: -$0.58
• Consensus EPS: -$0.67
• Beat/Miss: Beat by +$0.09
• One Year Ago EPS: N/A

Delcath Systems Revenue Results

• Actual Revenue: $0.50 million
• Expected Revenue: $0.73 million
• Beat/Miss: Missed by -$230.00 thousand
• YoY Revenue Growth: N/A

Delcath Systems Announcement Details

• Quarter: Q2 2023
• Date: 8/9/2023
• Time: N/A

Delcath Systems (NASDAQ:DCTH), an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.